Loading
Life sciences · Journal article
Acs Applied Materials & Interfaces · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract The immunosuppressive tumor microenvironment (TME) remains a major barrier to effective cancer immunotherapy, largely due to deficient activation of innate immune pathways and insufficient immune cell infiltration. To address this issue, we developed a hybrid biomimetic nanoplatform (CL8-BO NPs + CLPS) that encapsulates a near-infrared photothermal agent (L8-BO) and the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide, respectively, and is surface-functionalized with a mixed macrophage–red blood cell membrane, with the two components used in synergy. Upon 808 nm laser irradiation, L8-BO generated localized hyperthermia, inducing gasdermin D-dependent pyroptosis, which released cytosolic DNA and damage-associated molecular patterns to activate the stimulator of interferon genes (STING) pathway. Concurrently, released lipopolysaccharide engaged TLR4 signaling, potentiating innate immune activation. In a subcutaneous 4T1 breast carcinoma model, intratumoral administration of CL8-BO NPs followed by laser irradiation remodeled the immunosuppressive TME by promoting dendritic cell maturation, enhancing intratumoral CD8+ cytotoxic T lymphocyte infiltration by 5-fold, and suppressing regulatory T cells and myeloid-derived suppressor cells. The combination therapy inhibits tumor growth by over 90%. This nanoplatform provides a promising strategy for converting “cold” tumors into “hot” tumors through photothermal–triggered pyroptosis and synergistic STING/TLR4 activation in a localized delivery model.